COVID-19 Vaccines and Coverage

22 de diciembre de 2020
Actualizado el 18 de septiembre de 2021
Actualizado el 23 de noviembre de 2021
 

In the face of the COVID-19 pandemic, pharmaceutical companies have moved to produce vaccines. The Food and Drug Administration (FDA) awarded an Emergency Use Authorization (EUA) to three companies for their vaccines: Pfizer Más información sobre enlaces de terceros on Dec. 11, 2020, Moderna Más información sobre enlaces de terceros on Dec. 18, 2020, and Janssen Pharmaceutical Companies of Johnson & Johnson Más información sobre enlaces de terceros on Feb. 27, 2021. On Aug. 23, 2021, they granted full approval Más información sobre enlaces de terceros of the Pfizer COVID-19 vaccine for ages 16 and older. The Pfizer vaccine, known as Comirnaty is also available under EUA for ages 5-15. Vea el FDA website Más información sobre enlaces de terceros for prescribing information.

Booster Shots and Additional Doses: The federal government requires us to cover the COVID-19 vaccine at no cost share through the end of the public health emergency (PHE). This includes COVID-19 booster shots and additional doses. Members may choose to receive the vaccine type they originally received or a different type as a booster shot. CDC recommendations allow for mix-and-match dosing for booster shots. El centro móvil de atención (MAC, en inglés) de CDC provides guidance Más información sobre enlaces de terceros on the administration of the vaccine. At the end of the PHE, we will provide updates on our coverage.

Initially, the federal government will pay for the vaccine Más información sobre enlaces de terceros. Blue Cross and Blue Shield of New Mexico (BCBSNM), or self-funded groups, will cover administration of the vaccine as noted below:

Fully insured:

  • Vaccine and administration covered as a preventive service with no cost-share to members at in-network providers
  • Vaccine and administration covered with no cost-share to members if delivered at out-of-network providers through the end of the public health emergency

Self-funded employer groups:

  • Non-grandfathered self-funded employer groups - vaccine and administration covered as a preventive service with no cost-share to members at in-network providers
  • Vaccine and administration covered at no cost-share to members at out-of-network providers through the end of the public health emergency
  • Self-funded employer groups that don’t cover preventive vaccines through their pharmacy benefit must cover the vaccine through their medical benefit
  • Grandfathered plans are not required to cover preventive services, including the COVID-19 vaccine

Medicare Advantage

  • Through Dec. 31, 2021: Submit claims for the vaccine and its administration to the CMS Medicare Administrative Contractor using product-specific codes for each vaccine approved. Payment for the vaccine and its administration is through the original fee-for-service Medicare program until the end of 2021.
  • Starting Jan. 1, 2022: BCBSXX will cover the cost of COVID-19 vaccines and their administration for Medicare Advantage members. For Medicare Advantage members you vaccinate on or after Jan. 1, follow your normal submission process to BCBSXX or see the member’s ID card for billing instructions.
  • Medicare Advantage members will continue to have no cost-sharing during their 2022 benefit year on vaccines and their administration, including approved booster doses.

Coberturas Suplementarias Medicare

  • Submit claims for the vaccine and its administration to CMS. Payment is through the original fee-for-service Medicare program.

Medicaid

  • Most Medicaid members will have no cost-sharing on vaccines from in- and out-of-network providers. See the CMS Medicaid toolkitMás información sobre enlaces de terceros

Reimbursement:

  • Los profesionales de la red recibirán un reembolso de la tarifa de administración en función de las tarifas acordadas.
  • Out-of-network providers will be reimbursed based on established OON reimbursement policy that follows Medicare rates.

Balance billing: Providers are prohibited from billing patients for the vaccine or its administration, including balance billing, if the provider received the vaccine at no cost from the government.

Coding claims: CMS and the American Medical Association (AMA) have identified the codes to use in submitting claims. Para obtener más información, consulte CMS’ guidance Más información sobre enlaces de terceros.

When billing a vaccine administration code with an office visit, if the vaccine is not the primary purpose of the office visit, bill the vaccine on a separate claim.

Código

Utilice

Descripción

M0201

 Admin

Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home

D1701

 Admin

Pfizer-BioNTech Covid-19 vaccine administration – first dose

D1702

 Admin

Pfizer-BioNTech Covid-19 vaccine administration – second dose

D1703

 Admin

Moderna Covid-19 vaccine administration – first dose

D1704

 Admin

Moderna Covid-19 vaccine administration – second dose

D1707

 Admin

Janssen COVID-19 vaccine administration

0001A

 Admin

Pfizer-Biontech Covid-19 Vaccine Administration – First Dose ADM SARSCOV2 30MCG/0.3ML 1ST

0002A

 Admin

Pfizer-Biontech Covid-19 Vaccine Administration – Second Dose ADM SARSCOV2 30MCG/0.3ML 2ND

0003A

 Admin

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose

0011A

 Admin

Moderna Covid-19 Vaccine Administration – First Dose ADM SARSCOV2 100MCG/0.5ML1ST

0012A

 Admin

Moderna Covid-19 Vaccine Administration – Second Dose ADM SARSCOV2 100MCG/0.5ML2ND

00013A

 Admin

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose

0031A

 Admin

Janssen/Johnson & Johnson - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose

91300

Vacuna

Pfizer-Biontech Covid-19 Vaccine SARSCOV2 VAC 30MCG/0.3ML IM

91301

Vacuna

Moderna Covid-19 Vaccine SARSCOV2 VAC 100MCG/0.5ML IM

91303

Vacuna

Janssen/Johnson & Johnson - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use

Dosage: Candidate vaccines may require one or two doses. The Pfizer and Moderna vaccines require two doses. The Janssen/Johnson & Johnson vaccine is one dose. Guidance on additional doses is evolving. Seguir CDC guidelines Más información sobre enlaces de terceros

Más información:

  • CDC COVID-19 Vaccination Program Interim Playbook Más información sobre enlaces de terceros 
  • Provider Relief Fund Más información sobre enlaces de terceros– for reimbursement for administering the COVID-19 vaccine to the uninsured
  • CMS Medicaid Toolkit Más información sobre enlaces de terceros- Coverage and Reimbursement of COVID-19 Vaccines, Vaccine Administration, and Cost Sharing under Medicaid, the Children’s Health Insurance Program, and Basic Health Program
  • CMS guidance Más información sobre enlaces de terceros on Medicare billing for the COVid-19 vaccine administration

Seguimos controlando la información proporcionada por los CDC y otros funcionarios del gobierno y de la salud. Proporcionaremos actualizaciones cuando las tengamos. Si desea obtener información actualizada sobre el COVID-19, le recomendamos que visite el sitio web de los CDC sobre COVID-19 Más información sobre enlaces de terceros.

Más información sobre enlaces de tercerosAl hacer clic en este enlace, irá a un nuevo sitio web o a una aplicación ("sitio"). El sitio al que está por acceder podría ser administrado por un proveedor o un tercero. El sitio también podría proporcionarle información no relacionada con Medicare. Además, algunos sitios podrían solicitarle que acepte sus propios términos de uso y políticas de privacidad.